| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fb9885b61a0584fb8661e99b528b1ae |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2019-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_166b0f7d437ef6a53914345abeaa82a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5fc13a787095a4863760bd4f1f15934 |
| publicationDate |
2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020022323-A2 |
| titleOfInvention |
estriol component for use in the treatment of advanced breast cancer positive for estrogen receptor, oral dosage unit and parts kit |
| abstract |
the invention relates to the treatment of advanced estrogen receptor positive breast cancer in a subject who was treated with an estrogen suppressor selected from a selective estrogen receptor modulator (serm), an aromatase inhibitor and a anti-estrogen, said treatment comprising administration of an estriol component after treatment with an estrogen suppressant has been discontinued, said estriol component being selected from estriol, estriol prodrugs and combinations thereof. |
| priorityDate |
2018-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |